NM-01 was developed using genetically engineered, camelid-derived, single-domain antibodies. Radiopharm has additionally acquired the imaging rights of NM-01 from NanoMab for the Chinese market and worldwide intellectual property rights for any therapeutic use.
Radiopharm will soon initiate a phase I therapeutic trial in Australian patients with programmed cell death ligand 1 (PD-L1) positive non-small cell lung cancer. Radiopharm and Lantheus have agreed to cross-reference each other's data to facilitate development plans for the PD-L1 assets, including the regulatory process with the U.S. Food and Drug Administration and other key regulatory agencies.
Copyright © 2022 AuntMinnieEurope.com